Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.

L. Weiss,C. Harris,Marc Berger,H. Tanowitz,M. Wittner

DOI: https://doi.org/10.1093/INFDIS/157.3.580

1988-03-01

Abstract:

What problem does this paper attempt to address?

Betulinic acid exhibits antiviral effects against dengue virus infection

Marcus Wing Choy Loe,Erwei Hao,Meiling Chen,Cong Li,Regina Ching Hua Lee,Isabelle Xin Yu Zhu,Zi Yun Teo,Wei-Xin Chin,Xiaotao Hou,JiaGang Deng,Justin Jang Hann Chu

DOI: https://doi.org/10.1016/j.antiviral.2020.104954

IF: 7.6

2020-12-01

Antiviral Research

Abstract:Dengue virus is an arthropod-borne virus that has developed into a prominent global health threat in recent decades. The main causative agent of dengue fever, the virus infects an estimated 390 million individuals across the globe each year. Despite the sharply increasing social and economic burden on global society caused by the disease, there is still a glaring lack of effective therapeutics against DENV. In this study, betulinic acid, a naturally occurring pentacyclic triterpenoid was established as an inhibitor of DENV infection in vitro. Time-course studies revealed that betulinic acid inhibits a post-entry stage of the DENV replication cycle and subsequent analyses also showed that the compound is able to inhibit viral RNA synthesis and protein production. Betulinic acid also demonstrated antiviral efficacy against other serotypes of DENV, as well as against other mosquito-borne RNA viruses such as Zika virus and Chikungunya virus, which are commonly found co-circulating together with DENV. As such, betulinic acid may serve as a valuable starting point for the development of antivirals to combat potential DENV outbreaks, particularly in tropical and subtropical regions which make up a large majority of documented infections.

pharmacology & pharmacy,virology
Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection

Yi-Jung Huang,Tian-Lu Cheng,Yen-Tseng Wang,Chien-Shu Chen,Yu-Ling Leu,Chih-Shiang Chang,Cheng-Han Ho,Shi-Wei Chao,Chia-Tse Li,Chih-Hung Chuang

DOI: https://doi.org/10.1128/jvi.01258-23

IF: 6.549

2024-03-28

Journal of Virology

Abstract:ABSTRACT Dengue fever, an infectious disease prevalent in subtropical and tropical regions, currently lacks effective small-molecule drugs as treatment. In this study, we used a fluorescence peptide cleavage assay to screen seven compounds to assess their inhibition of the dengue virus (DENV) NS2B-NS3 protease. DV-B-120 demonstrated superior inhibition of NS2B-NS3 protease activity and lower toxicity compared to ARDP0006. The selectivity index of DV-B-120 was higher than that of ARDP0006. In vivo assessments of the antiviral efficacy of DV-B-120 against DENV replication demonstrated delayed mortality of suckling mice treated with the compound, with 60–80% protection against life-threatening effects, compared to the outcomes of DENV-infected mice treated with saline. The lower clinical scores of DENV-infected mice treated with DV-B-120 indicated a reduction in acute–progressive illness symptoms, underscoring the potential therapeutic impact of DV-B-120. Investigations of DV-B-120's ability to restore the antiviral type I IFN response in the brain tissue of DENV-infected ICR suckling mice demonstrated its capacity to stimulate IFN and antiviral IFN-stimulated gene expression. DV-B-120 not only significantly delayed DENV-2-induced mortality and illness symptoms but also reduced viral numbers in the brain, ultimately restoring the innate antiviral response. These findings strongly suggest that DV-B-120 holds promise as a therapeutic agent against DENV infection and highlight its potential contribution in addressing the current lack of effective treatments for this infectious disease. IMPORTANCE The prevalence of dengue virus (DENV) infection in tropical and subtropical regions is escalating due to factors like climate change and mosquito vector expansion. With over 300 million annual infections and potentially fatal outcomes, the urgent need for effective treatments is evident. While the approved Dengvaxia vaccine has variable efficacy, there are currently no antiviral drugs for DENV. This study explores seven compounds targeting the NS2B-NS3 protease, a crucial protein in DENV replication. These compounds exhibit inhibitory effects on DENV-2 NS2B-NS3, holding promise for disrupting viral replication and preventing severe manifestations. However, further research, including animal testing, is imperative to assess therapeutic efficacy and potential toxicity. Developing safe and potent treatments for DENV infection is critical in addressing the rising global health threat posed by this virus.

virology
Climate change epidemiology: methodological challenges

Wei W. Xun,A. Khan,Edwin Michael,P. Vineis

DOI: https://doi.org/10.1007/s00038-009-0091-1

2010-04-01

International Journal of Public Health

Abstract:
Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.

Zhigang Zhou,Mansoora Khaliq,Jae-Eun Suk,Chinmay Patkar,Long Li,Richard J. Kuhn,Carol Beth Post

DOI: https://doi.org/10.1021/cb800176t

IF: 4.634

2008-01-01

ACS Chemical Biology

Abstract:Infection by the mosquito-borne dengue virus causes dengue fever and the sometimes fatal dengue hemorrhagic fever. The increasing number of dengue infections per year suggests that the virus is becoming more virulent and its transmission is expanding. Nevertheless, no effective treatment for dengue infection currently exists. In a search for antiviral agents effective against dengue virus, we investigated the potential of targeting a structural protein site rather than an enzymatic one. Using this approach, we now report the discovery of a small molecule ligand that inhibits viral growth. Our results also provide the first evidence that the binding site, a pocket located at the hinge between domains 1 and 2 of the envelope protein (E protein) on the virus surface, is a valid target for antiviral therapy. Ligand candidates were identified from libraries of approximately 142,000 compounds using a computational high-throughput screening protocol targeting this pocket of the E protein. Cell-based assays were conducted on 23 top-ranked compounds. Among four with good antiviral activity profiles, the compound P02 was found to inhibit viral reproduction at micromolar concentrations. Using saturation transfer difference NMR spectroscopy, we also show that the compound binds virus and competes for binding E protein with the known ligand N-octyl-beta-D-glucoside. Together, the results are consistent with an inhibition mechanism against maturation or host-cell entry mediated by ligand binding to the E-protein pocket. P02 is a promising lead compound for future development of an effective treatment against dengue virus and related flaviviruses.
Effects of the oxoaporphine alkaloid hernandonine on dengue virus. Evidence for its mechanisms of action

Ying-Chieh Liao,Chih-Ching Yeh,Yu-Fan Chueh,Mei-Shu Huang,Jhong-Syuan Wu,Ying-Xu Wen,Yu-Tzu Chang,Yi-Ru Lai,Jih-Jung Chen,Tsung-Hsien Chang

DOI: https://doi.org/10.1016/j.phymed.2024.155986

IF: 6.656

2024-08-27

Phytomedicine

Abstract:Background: Dengue, caused by the dengue virus (Orthoflavivirus dengue, encompassing DENV types 1-4), is a member of the Flaviviridae family. The symptoms of dengue range from subclinical or mild manifestations to potentially fatal complications. The management of severe dengue is exceptionally challenging due to the absence of effective antiviral medications. In this context, natural products, whether in the form of pure compounds or standardized plant extracts, have emerged as a promising source for the development of novel antiviral therapeutics. Hernandonine, an oxoaporphine alkaloid found in Hernandia nymphaeifolia (C. Presl) Kubitzki. serves both as a metabolite and an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase. Purpose: This study investigated the ability of hernandonine to inhibit DENV infection and explored its potential mechanisms. Study design: To assess the in vitro anti-DENV activity, cells or induced pluripotent stem cell (iPSC)-derived cerebral organoids were exposed to hernandonine before or after infection with DENV. Along with hernandonine, the endocytosis modulators, genistein, wortmannin, Methyl-β-cyclodextrin (MβCD) and lovastatin, were used in the assays. Methods: The DENV infectivity and virion production in cells or cerebral organoids treated with compounds were determined. Various methods, including cell and cerebral organoids imaging, protein and gene detection were conducted to explore their antiviral mechanisms. Results: The results revealed notable antiviral properties of hernandonine, particularly in inhibiting DENV during the early stages of infection. Mechanistic analysis demonstrated that, akin to genistein, wortmannin, methyl-β-cyclodextrin (MβCD), and lovastatin, hernandonine exerted an influence on cholesterol-rich lipid rafts. It also restrained the pseudopodial movement ability of cells, potentially through the downregulation of cytoskeleton and endocytosis regulatory genes or protein expression. Moreover, hernandonine's virucidal activity was demonstrated. Hernandonine's inhibition of DENV infection was further validated in a disease-relevant iPSC-derived cerebral organoids model, a novel DENV-2 infection system worthy of further application. Conclusion: This study evidenced the potential of hernandonine as a novel candidate in the fight against DENV infection.
Identification of an effective fraction from Ampelopsis Radix with anti-dengue virus activities in vitro and in vivo

Chunyang Tian,Hefei Huang,Yuanru Zheng,Xuemei He,Lijun Yan,Lingzhu Shi,Tangjia Yang,Xi Chen,Jiabin Yang,Zibin Lu,Huihui Cao,Wei Zhao,Zhiran Qin,Jianhai Yu,Qingfa Tang,Xiankun Tong,Junshan Liu,Linzhong Yu

DOI: https://doi.org/10.1016/j.jep.2023.116339

2023-06-12

Abstract:Ethnopharmacological relevance: Dengue virus (DENV) infection is a global public health issue without effective therapeutic interventions. Chinese medicine with heat-clearing and detoxifying properties has been frequently used in the treatment of viral infection. Ampelopsis Radix (AR) is a traditional Chinese medicine for clearing heat and detoxification that has been widely used in the prevention and treatment of infectious diseases. However, no studies on the effects of AR against viral infection have been reported, thus far. Aim of the study: To explore the anti-DENV activities of the fraction (AR-1) obtained from AR both in vitro and in vivo. Materials and methods: The chemical composition of AR-1 was identified by liquid chromatography-tandem MS (LC‒MS/MS). The antiviral activities of AR-1 were studied in baby hamster kidney fibroblast BHK-21 cells, ICR suckling mice and induction of interferon α/β (IFN-α/β) and IFN-γ R-/- (AG129) mice. Results: Based on LC‒MS/MS analysis, 60 compounds (including flavonoids, phenols, anthraquinones, alkaloids and other types) were tentatively characterized from AR-1. AR-1 inhibited the cytopathic effect, the production of progeny virus and the synthesis of viral RNA and proteins by blocking DENV-2 binding to BHK-21 cells. Moreover, AR-1 significantly attenuated weight loss, decreased clinical scores and prolonged the survival of DENV-infected ICR suckling mice. Critically, the viral load in blood, brain and kidney tissues and the pathological changes in brain were remarkably alleviated after AR-1 treatment. Further study on AG129 mice showed that AR-1 obviously improved the clinical manifestations and survival rate, reduced viremia, attenuated gastric distension and relieved the pathological lesions caused by DENV. Conclusions: In summary, this is the first report that AR-1 exhibits anti-DENV effects both in vitro and in vivo, which suggests that AR-1 may be developed as a therapeutic candidate against DENV infection.
Liang-Ge-San inhibits dengue virus serotype 2 infection by reducing caveolin1-induced cytoplasmic heat shock protein 70 translocation into the plasma membrane

Xi Chen,Jia-Bin Yang,Hui-Hui Cao,Xiao-Chuan Fang,Shan-Hong Liu,Li-Fang Zou,Jian-Hai Yu,Jian-Ping Zuo,Wei Zhao,Zi-Bin Lu,Jun-Shan Liu,Lin-Zhong Yu,Jia-bin Yang,Hui-hui Cao,Xiao-chuan Fang,Shan-hong Liu,Li-fang Zou,Jian-hai Yu,Jian-ping Zuo,Zi-bin Lu,Jun-shan Liu,Lin-zhong Yu

DOI: https://doi.org/10.1016/j.phymed.2023.154977

IF: 6.656

2023-07-28

Phytomedicine

Abstract:Background Dengue virus (DENV) is a major public health threat. However, there are no specific therapeutic drugs for DENV. Many Chinese heat-cleaning formulas, such as Liang-Ge-San (LGS), have been frequently used in the virus-induced diseases. The antiviral effect of LGS has not been reported yet. Purpose In this study, the effect of LGS on the inhibition of dengue virus serotype 2 (DENV-2) was investigated and the relevant mechanism was explored. Methods High-performance liquid chromatography was applied to analyze the chemical characterization of LGS. The in vitro antiviral activities of LGS against DENV-2 were evaluated by time-of-drug-addition assay. The binding of heat shock protein 70 (Hsp70) and envelope (E) protein or caveolin1 (Cav1) were analyzed by immunofluorescence and immunoprecipitation assays. Then the role of Cav1 in the anti-DENV-2 effects of LGS was further examined. DENV-2 infected Institute of Cancer Research suckling mice ( n = 10) and AG129 mice ( n = 8) were used to examine the protective effects of LGS. Results It was found that geniposide, liquiritin, forsythenside A, forsythin, baicalin, baicalein, rhein, and emodin maybe the characteristic components of LGS. LGS inhibited the early stage of DENV-2 infection, decreased the expression levels of viral E and non-structural protein 1 (NS1) proteins. LGS also reduced E protein and Hsp70 binding and attenuated the translocation of Hsp70 from cytoplasm to the cell membrane. Moreover, LGS decreased the binding of Hsp70 to Cav1. Further study showed that the overexpression of Cav1 reversed LGS-mediated E protein and Hsp70 inhibition in the plasma membrane. In the in vivo study, LGS was highly effective in prolonging the survival time, reducing viral loads. Conclusion This work demonstrates for the first time that LGS exerts anti-DENV-2 activity in vitro and in vivo . LGS decreases DENV-2-stimulated cytoplasmic Hsp70 translocation into the plasma membrane by Cav1 inhibition, thereby inhibiting the early stage of virus infection. These findings indicate that LGS may be a candidate for the treatment of DENV.

pharmacology & pharmacy,chemistry, medicinal,integrative & complementary medicine,plant sciences
Antiviral activity of silymarin and baicalein against dengue virus

Zhao Xuan Low,Brian Ming OuYong,Pouya Hassandarvish,Chit Laa Poh,Babu Ramanathan

DOI: https://doi.org/10.1038/s41598-021-98949-y

IF: 4.6

2021-10-27

Scientific Reports

Abstract:Abstract Dengue is an arthropod-borne viral disease that has become endemic and a global threat in many countries with no effective antiviral drug available currently. This study showed that flavonoids: silymarin and baicalein could inhibit the dengue virus in vitro and were well tolerated in Vero cells with a half-maximum cytotoxic concentration (CC 50 ) of 749.70 μg/mL and 271.03 μg/mL, respectively. Silymarin and baicalein exerted virucidal effects against DENV-3, with a selective index (SI) of 10.87 and 21.34, respectively. Baicalein showed a better inhibition of intracellular DENV-3 progeny with a SI of 7.82 compared to silymarin. Baicalein effectively blocked DENV-3 attachment (95.59%) to the Vero cells, while silymarin prevented the viral entry (72.46%) into the cells, thus reducing viral infectivity. Both flavonoids showed promising antiviral activity against all four dengue serotypes. The in silico molecular docking showed that silymarin could bind to the viral envelope (E) protein with a binding affinity of − 8.5 kcal/mol and form hydrogen bonds with the amino acids GLN120, TRP229, ASN89, and THR223 of the E protein. Overall, this study showed that silymarin and baicalein exhibited potential anti-DENV activity and could serve as promising antiviral agents for further development against dengue infection.

multidisciplinary sciences
Discovery of Dengue Virus Ns4b Inhibitors

Qing-Yin Wang,Hongping Dong,Bin Zou,Ratna Karuna,Kah Fei Wan,Jing Zou,Agatha Susila,Andy Yip,Chao Shan,Kim Long Yeo,Haoying Xu,Mei Ding,Wai Ling Chan,Feng Gu,Peck Gee Seah,Wei Liu,Suresh B. Lakshminarayana,CongBao Kang,Julien Lescar,Francesca Blasco,Paul W. Smith,Pei-Yong Shi

DOI: https://doi.org/10.1128/jvi.00855-15

IF: 6.549

2015-01-01

Journal of Virology

Abstract:ABSTRACT The four serotypes of dengue virus (DENV-1 to -4) represent the most prevalent mosquito-borne viral pathogens in humans. No clinically approved vaccine or antiviral is currently available for DENV. Here we report a spiropyrazolopyridone compound that potently inhibits DENV both in vitro and in vivo. The inhibitor was identified through screening of a 1.8-million-compound library by using a DENV-2 replicon assay. The compound selectively inhibits DENV-2 and -3 (50% effective concentration [EC50], 10 to 80 nM) but not DENV-1 and -4 (EC50, >20 μM). Resistance analysis showed that a mutation at amino acid 63 of DENV-2 NS4B (a nonenzymatic transmembrane protein and a component of the viral replication complex) could confer resistance to compound inhibition. Genetic studies demonstrate that variations at amino acid 63 of viral NS4B are responsible for the selective inhibition of DENV-2 and -3. Medicinal chemistry improved the physicochemical properties of the initial “hit” (compound 1), leading to compound 14a, which has good in vivo pharmacokinetics. Treatment of DENV-2-infected AG129 mice with compound 14a suppressed viremia, even when the treatment started after viral infection. The results have proven the concept that inhibitors of NS4B could potentially be developed for clinical treatment of DENV infection. Compound 14a represents a potential preclinical candidate for treatment of DENV-2- and -3-infected patients. IMPORTANCE Dengue virus (DENV) threatens up to 2.5 billion people and is now spreading in many regions in the world where it was not previously endemic. While there are several promising vaccine candidates in clinical trials, approved vaccines or antivirals are not yet available. Here we describe the identification and characterization of a spiropyrazolopyridone as a novel inhibitor of DENV by targeting the viral NS4B protein. The compound potently inhibits two of the four serotypes of DENV (DENV-2 and -3) both in vitro and in vivo. Our results validate, for the first time, that NS4B inhibitors could potentially be developed for antiviral therapy for treatment of DENV infection in humans.
Inhibition of Dengue Virus by an Ester Prodrug of an Adenosine Analog

Yen-Liang Chen,Zheng Yin,Suresh B. Lakshminarayana,Min Qing,Wouter Schul,Jeyaraj Duraiswamy,Ravinder Reddi Kondreddi,Anne Goh,Hao Ying Xu,Andy Yip,Boping Liu,Margaret Weaver,Veronique Dartois,Thomas H. Keller,Pei-Yong Shi

DOI: https://doi.org/10.1128/aac.00397-10

IF: 5.938

2010-01-01

Antimicrobial Agents and Chemotherapy

Abstract:Dengue virus (DENV) is the most prevalent mosquito-borne viral pathogen that infects humans. Neither a vaccine nor an antiviral therapy is currently available for DENV. Here, we report an adenosine nucleoside prodrug that potently inhibits DENV replication both in cell culture and in a DENV mouse model. NITD449 (2'-C-acetylene-7-deaza-7-carbamoyladenosine) was initially identified as a parental compound that inhibits all four serotypes of DENV with low cytotoxicity. However, in vivo pharmacokinetic studies indicated that NITD449 had a low level of exposure in plasma when dosed orally. To increase the oral bioavailability, we covalently linked isobutyric acids to the 3'- and 5'-hydroxyl groups of ribose via ester linkage to NITD449, leading to the prodrug NITD203 (3',5'-O-diisobutyryl-2'-C-acetylene-7-deaza-7-carbamoyl-adenosin). Pharmacokinetic analysis showed that upon oral dosing of the prodrug, NITD203 was readily converted to NITD449, resulting in improved exposure of the parental compound in plasma in both mouse and rat. In DENV-infected AG129 mice, oral dosing of the prodrug at 25 mg/kg of body weight reduced peak viremia by 30-fold. Antiviral spectrum analysis showed that NITD203 inhibited various flaviviruses (DENV, yellow fever virus, and West Nile virus) and hepatitis C virus but not Chikungunya virus (an alphavirus). Mode-of-action analysis, using a luciferase-reporting replicon, indicated that NITD203 inhibited DENV RNA synthesis. Although NITD203 exhibited potent in vitro and in vivo efficacies, the compound could not reach a satisfactory no-observable-adverse-effect level (NOAEL) in a 2-week in vivo toxicity study. Nevertheless, our results demonstrate that a prodrug approach using a nucleoside analog could potentially be developed for flavivirus antiviral therapy.
Quassinoids from Eurycoma longifolia with antiviral activities by inhibiting dengue virus replication

Xuemei He,Yuanru Zheng,Chunyang Tian,Ting Wen,Tangjia Yang,Jingtao Yu,Xiaochuan Fang,Chunlin Fan,Junshan Liu,Linzhong Yu

DOI: https://doi.org/10.1016/j.phymed.2023.154650

IF: 6.656

Phytomedicine

Abstract:Background: Dengue caused by dengue virus (DENV) spreads rapidly around the world. However, there are no worldwide licensed vaccines or specific antivirals to combat DENV infection. Quassinoids are the most characteristic components of Eurycoma longifolia, which have been reported to display a variety of biological activities. However, whether quassinoids exert anti-DENV activities remains unknown. Purpose: To test the quassinoids of E. longifolia for their activity against DENV and to clarify the potential mechanisms. Methods: The quassinoids from E. longifolia were isolated by chromatography techniques, and their chemical structures were elucidated by spectroscopic analysis. The anti-DENV activities of quassinoids on baby hamster kidney cells BHK-21 were determined by lactate dehydrogenase (LDH) assay. The synthesis of progeny virus was measured by plaque assay. The expression levels of envelope protein (E) and non-structural protein 1 (NS1) were evaluated by qRT-PCR, Western blot and immunofluorescence assays. Molecular docking was used to screen the potential targets of the most active quassinoid against DENV-2, and surface plasmon resonance analysis was employed to confirm the direct binding between the most active quassinoid and potential target. Results: Twenty-four quassinoids, including three new quassinoids (1 - 3), were isolated from the ethanol extract of E. longifolia. Quassinoids 4, 5, 9, 11, 12, 15, 16, 17, 19 and 20 significantly reduced the LDH release at the stages of viral binding and entry or intracellular replication. Among them, 19 (6α-hydroxyeurycomalactone, 6α-HEL) exhibited the best anti-DENV-2 activities with an EC50 value of 0.39 ± 0.02 μM. Further experiments suggested that 6α-HEL remarkably inhibited progeny virus synthesis and mRNA and protein expression levels of E and NS1 of DENV-2. Time-of-drug-addition assay suggested that 6α-HEL inhibited intracellular replication of DENV-2 at an early stage. Moreover, 6α-HEL was shown to interact with NS5-RdRp domain at a binding affinity of -8.15 kcal/mol. SPR assay further verified 6α-HEL bound to RdRp protein with an equilibrium dissociation constant of 1.49 × 10-7 M. Conclusion: Ten quassinoids from E. longifolia showed anti-DENV activities at processes of virus binding and entry or intracellular replication. The most active quassinoid 6α-HEL exerts the anti-DENV-2 activities at intracellular replication stage by directly targeting the NS5-RdRp protein. These results suggest that 6α-HEL could be a promising candidate for the treatment of DENV-2 infection.
Réarrangements chromosomiques dans les génomes de mammifères : caractérisation des points de cassure. (Chromosomal rearrangements in mammalian genomes : characterising the breakpoints)

C. Lemaitre

2008-11-06

Abstract:Les rearrangements chromosomiques sont des mutations qui modifient la structure et l'organisation des genomes. Ils sont ici etudies dans le cadre de l'evolution des genomes de mammiferes. L'objectif de ces travaux est de caracteriser les regions du genome qui ont subi de tels evenements; elles sont appelees des points de cassure. Dans un premier temps, nous avons developpe une methode permettant d'identifier precisement ces regions sur un genome par comparaison avec un genome d'espece differente. Nous montrons qu'elle ameliore nettement la resolution par rapport aux methodes existantes. Cela permet, dans un deuxieme temps, d'analyser le contenu des sequences de points de cassure et leur repartition le long du genome. Plusieurs caracteristiques de sequences ont ainsi ete identifiees dans les points de cassure chez l'homme, comme la perte de similarite avec les genomes compares et la presence de duplications et d'elements transposables. Enfin, nous montrons que les points de cassure ne sont pas repartis uniformement le long du genome, mais leur localisation serait fortement influencee par l'organisation des genes et la structuration du genome en isochores.
The identification of active compounds in Ganoderma lucidum var. antler extract inhibiting dengue virus serine protease and its computational studies

Wui Zhuan Lim,Poh Guat Cheng,Ammar Yasir Abdulrahman,Teow Chong Teoh

DOI: https://doi.org/10.1080/07391102.2019.1678523

2019-10-24

Journal of Biomolecular Structure and Dynamics

Abstract:The number of global dengue incidences is alarmingly high in recent years. The global distribution of four dengue serotypes has also added economic burden in the dengue-endemic countries. To discover the potent dengue virus inhibitors in the antler form of Ganoderma lucidum (Lingzhi or Reishi), the water extraction of normal G. lucidum and its antler form were conducted and the chemical compounds were identified by LC-MS. Six distinct chemical compounds identified in high abundance were hesperetin, thymidine, lucidenic acid, 11-aminoundecanoic acid, 5-carboxyvanillic acid and ganocin B. The water extracts of G. lucidum in its antler form inhibited the DENV2 NS2B-NS3 protease activity at 84.6 ± 0.7%, higher than the normal G. lucidum. Then, molecular docking was performed on the homology model built from an in-house sequence. Docking simulation results showed that hesperetin and ganocin B were the best leads to bind at the catalytic triad of DENV2 NS2B-NS3pro via hydrogen bonding, van der Waals and pi-pi interactions. Extensive overlapping of HOMO-LUMO orbitals at the ringed regions of hesperetin helped to facilitate the entry of ligand to the catalytic triad cleft. LC-MS, molecular docking and density functional theory analyses confirmed that hesperetin was the strongest inhibitor against NS2B-NS3 protease.Communicated by Ramaswamy H. Sarma
Molecular docking and dynamics simulation reveal withanolides as potent antivirals against dengue virus

Michelle Felicia Lee,Sang Loon Tan,Nafees Ahemad,Azzmer Azzar Abdul Hamid,Siti Aishah Sufira Nor Hishamuddin,Kalaivani Batumalaie,Sheryar Afzal,Yuan Seng Wu

DOI: https://doi.org/10.1016/j.sajb.2024.04.045

IF: 3.111

2024-05-07

South African Journal of Botany

Abstract:The prevalence of dengue remains a significant global threat to public health with millions of infections reported annually due to the lack of effective treatment options. Natural resources such as plants contain phytochemicals with desirable therapeutic effects. For instance, the Indian ginseng, Withania somnifera L. (Solanaceae), contains steroidal lactones, saponins, glycosides, and alkaloids which possessed antiviral activities against various viruses. In this study, docking analysis of seven compounds and phytochemicals were performed against the structural and non-structural (NS) proteins of all four dengue virus (DENV) serotypes as well as host cell receptors such as DC-SIGN and CLEC5A. Withanolide A (L5) was selected as the best inhibitor with high binding affinities towards ten targets consisting of DENV structural and NS proteins as well as the CLEC5A receptor. L5 also showed a fair stability with DENV1, DENV2, and DENV3 over a time span of 100 ns via molecular dynamics simulation. L5 demonstrated good drug-likeness properties, a moderate bioavailability score of 0.55, and is predicted to have high gastrointestinal absorptivity. The data from this in silico study revealed the potential of withanolide A to be further developed as an antiviral against dengue. This is the first study to report the in silico analyses of phytochemicals derived from W. somnifera L. (Solanaceae) against the viral proteins of DENV1 to 4 and their respective host cell receptors.

plant sciences
exploration of potent flavonoids for dengue therapeutics

Anuraj Phunyal,Achyut Adhikari,Jhashanath Adhikari Subin

DOI: https://doi.org/10.1101/2024.03.24.586491

2024-03-28

Abstract:Dengue poses a persistent and widespread threat with no effective antiviral drug available till now. Several inhibitors have been developed by targeting the viral non-structural proteins including methyl transferase (NS5) of the dengue virus with possible therapeutic values. In this work, virtual screening, molecular docking, molecular dynamics simulations (200 ns), and assessments of free energy changes to identify potential candidates from a database of flavonoids ( 2000) that may have good curative potential from the disease. The binding affinity of flavonoids, namely Genistein-7-glucoside (FLD1), 6’–O-Acetylgenistin (FLD2), 5,6-dihydroxy-2-(4-hydroxyphenyl)-7-[3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-yl]oxychromen-4-one (FLD3), Glucoliquiritigenin (FLD4), and Chrysin-7-O-glucoronide (FLD5) showed the binding affinities of −10.2, −10.2, −10.1, −10.1, −9.9 kcal/mol, respectively, and possessed better values than that of the native ligand with showed (−7.6 kcal/mol) and diclofenac sodium (−7.3 kcal/mol). Drug-likeness of these compounds was acceptable and no toxicity was hinted by ADMET predictions. The stability of the protein-ligand complexes was accessed from 200 ns molecular dynamics simulation in terms of various geometrical parameters; RMSD, RMSF of residues, Rg, SASA, and H-bond of the protein-ligand complexes. The binding free energy changes of these compounds were calculated by the MM-PBSA solvation model with negative values (less than −38.01±7.53 kcal/mol) indicating the spontaneity of the forward reaction and favorability of the product formation. The geometrical and thermodynamic parameters infer that the flavonoid binds at the orthosteric site of the target protein of DENV-2 and could inhibit its functioning resulting in the prevention of the disease. Overall, this study highlights the anti-DENV activity of five flavonoids, positioning them as promising candidates for further development as antiviral agents against dengue infection.

Bioinformatics
Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy

Min-Hsuan Lin,Pramila Maniam,Dongsheng Li,Bing Tang,Cameron Bishop,Andreas Suhrbier,Lucy Wales-Earl,Yaman Tayyar,Nigel A. J. McMillan,Li Li,David Harrich

DOI: https://doi.org/10.1101/2024.04.23.590664

2024-05-16

Abstract:Presently, no approved antiviral drug targets dengue virus (DENV) infection. Treatment mainly relies on supportive measures, while the efficacy of DENV vaccines varies based on factors like vaccine type, circulating DENV serotypes, and the vaccinated population. This study explores using defective interfering particles (DIPs) and lipid nanoparticles (LNPs) to deliver an anti-DENV defective interfering (DI) RNA, known as DI290. Our results showed that both DIPs and DI290 loaded LNPs (LNP-290) effectively suppressed DENV infection in human primary monocyte-derived macrophages (MDMs), THP-1 macrophages and human fibroblasts, representing cell types naturally targeted by DENV. Furthermore, LNP-290 demonstrated inhibition of DENV infection in IFNAR-deficient mice, which lack functional type I interferon (IFN) receptors, leading to decreased viremia and viral replication levels. We then proceeded to examine the involvement of IFN regulatory factor (IRF) 3 and IRF7 in facilitating DI290 RNA-triggered antiviral reactions via retinoic acid-inducible gene I (RIG-I)-like receptors (RLRs) using IRF3/IRF7 DKO mice, double knockout for IRF3 and IRF7. LNP-DI290 completely inhibited DENV infection in these DKO mice, indicating that DI290 RNA induced an IFN-mediated cellular antiviral state by a noncanonical pathway. Examination of RNA-Seq data from LNP-treated C57BL/6J mice and IFNAR-deficient mice, along with human MDMs treated with LNPs or DENV DIPs, showed that DI290 RNA treatment notably heightened IFN responses, particularly IFNγ, as well as IFNα/β and IFNλ. Furthermore, administering LNP-290 to mice did not manifest apparent adverse effects on their welfare. In summary, these experiments suggest that DI290 RNA shows potential as a therapeutic approach for combating DENV infection.

Microbiology
Inhibition of dengue viruses by N-methylcytisine thio derivatives through targeting viral envelope protein and NS2B-NS3 protease

Chen-Sheng Lin,Chih-Hao Lu,Tsai-Hsiu Lin,Yan-Tung Kiu,Ju-Ying Kan,Yu-Jen Chang,Ping-Yi Hung,Alena V Koval'skaya,Dmitry O Tsypyshev,Inna P Tsypysheva,Cheng-Wen Lin,Alena V. Koval'skaya,Dmitry O. Tsypyshev,Inna P. Tsypysheva

DOI: https://doi.org/10.1016/j.bmcl.2024.129623

IF: 2.94

2024-02-01

Bioorganic & Medicinal Chemistry Letters

Abstract:Dengue virus (DENV) is a significant global health threat, causing millions of cases worldwide each year. Developing antiviral drugs for DENV has been a challenging endeavor. Our previous study identified anti-DENV properties of two (-)-cytisine derivatives contained substitutions within the 2-pyridone core from a pool of 19 (-)-cytisine derivatives. This study aimed to expand on the previous research by investigating the antiviral potential of N-methylcytisine thio (mCy thio) derivatives against DENV, understanding the molecular mechanisms of antiviral activity for the active thio derivatives. The inhibitory assays on DENV-2-induced cytopathic effect and infectivity revealed that mCy thio derivatives 3 ((1R,5S)-3-methyl-1,2,3,4,5,6-hexahydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocine-8-thione) and 6 ((1S,5R)-3-methyl-2-thioxo-1,2,3,4,5,6-hexahydro-8H-1,5-methanopyrido[1,2-a][1,5]diazocin-8-one) were identified as the active compounds against both DENV-1 and DENV-2. Derivative 6 displayed robust antiviral activity against DENV-2, with EC50 values ranging from 0.002 to 0.005 μM in different cell lines. Derivative 3 also exhibited significant antiviral activity against DENV-2. The study found that these compounds are effective at inhibiting DENV-2 at both the entry stage (including virus attachment) and post-entry stages of the viral life cycle. The study also investigated the inhibition of the DENV-2 NS2B-NS3 protease activity by these compounds. Derivative 6 demonstrated notably stronger inhibition compared to mCy thio 3, revealing its dual antiviral action at both the entry and post-entry stages. Molecular docking simulations indicated that mCy thio derivatives 3 and 6 bind to the domain I and III of the DENV E protein, as well as the active of NS2B-NS3 protease, suggesting their molecular interactions with the virus. The study demonstrates the antiviral efficacy of N-methylcytisine thio derivatives against DENV. It provides valuable insights into the potential interactions between these compounds and viral target proteins, which could be useful in the development of antiviral drugs for DENV.

chemistry, medicinal, organic
An Adenosine Nucleoside Inhibitor of Dengue Virus.

Wouter Schul,Yen-Liang Chen,Zheng Yin,Thomas Keller,Pei-Yong Shi

DOI: https://doi.org/10.1016/j.antiviral.2010.02.347

IF: 7.6

2015-01-01

Antiviral Research

Abstract:Dengue virus (DENV), a mosquito-borne flavivirus, is a major public health threat. The virus poses risk to 2.5 billion people worldwide and causes 50 to 100 million human infections each year. Neither a vaccine nor an antiviral therapy is currently available for prevention and treatment of DENV infection. Here, we report a previously undescribed adenosine analog, NITD008, that potently inhibits DENV both in vitro and in vivo. In addition to the 4 serotypes of DENV, NITD008 inhibits other flaviviruses, including West Nile virus, yellow fever virus, and Powassan virus. The compound also suppresses hepatitis C virus, but it does not inhibit nonflaviviruses, such as Western equine encephalitis virus and vesicular stomatitis virus. A triphosphate form of NITD008 directly inhibits the RNA-dependent RNA polymerase activity of DENV, indicating that the compound functions as a chain terminator during viral RNA synthesis. NITD008 has good in vivo pharmacokinetic properties and is biologically available through oral administration. Treatment of DENV-infected mice with NITD008 suppressed peak viremia, reduced cytokine elevation, and completely prevented the infected mice from death. No observed adverse effect level (NOAEL) was achieved when rats were orally dosed with NITD008 at 50 mg/kg daily for 1 week. However, NOAEL could not be accomplished when rats and dogs were dosed daily for 2 weeks. Nevertheless, our results have proved the concept that a nucleoside inhibitor could be developed for potential treatment of flavivirus infections.
[Cancer--an environmental product?].

R. J. Harris

Abstract:
Design, synthesis, discovery and SAR of the fused tricyclic derivatives of indoline and imidazolidinone against DENV replication and infection

Weiyi Qian,Jian-Xia Xue,Jinxin Xu,Feng Li,Guang-Feng Zhou,Fang Wang,Rong-Hua Luo,Jinsong Liu,Yong-Tang Zheng,Guo-Chun Zhou

DOI: https://doi.org/10.1016/j.bioorg.2022.105639

IF: 5.307

2022-03-01

Bioorganic Chemistry

Abstract:Dengue virus, belonging to a genus Flavivirus, caused public health problem in recent years. One controversial vaccine of DENV was approved and there is no antiviral for the clinic treatment of DENV, therefore, efficient antivirals to DENV are of great medical significance. In this study, we conducted the design, synthesis, cell-based and target-based activity evaluation of 28 compounds based on indoline structural skeleton against DENV infection. Among them, 13 active compounds against DENV infection were discovered and their structure-activity relationship (SAR) was summarized. In this study, indoline carbohydrazine has derived more active compounds than indoline carboamide. It is discovered that TBS group exhibits a good pharmacophore to enhance anti-DENV activity. Further exploration indicated that post-treatment acts as effective time of addition and compound 15 targeting the post-entry stages of DENV2 viral life cycle. SPR imaging results support there are strong interaction of 13 and 15 with RdRp and compounds 13 and 15 reduce RdRp enzymatic activity, revealing that RdRp of DENV NS5 is the drug target for these series of compounds. Molecular docking deciphered the relationship of the structural feature with the putative binding mode by 13 and 15 with RdRp domain of DENV2 NS5 by hydrogen bonds and hydrophobic interactions to establish the fitted low energy conformation. Future studies will focus on designing more potent inhibitors for the treatment and prevention of dengue virus replication and infection, and understanding the more profound underlying structural features of inhibitors and drug action of the mechanism.

biochemistry & molecular biology,chemistry, organic

Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS.

Betulinic acid exhibits antiviral effects against dengue virus infection

Exploring the therapeutic potential of DV-B-120 as an inhibitor of dengue virus infection

Climate change epidemiology: methodological challenges

Antiviral compounds discovered by virtual screening of small-molecule libraries against dengue virus E protein.

Effects of the oxoaporphine alkaloid hernandonine on dengue virus. Evidence for its mechanisms of action

Identification of an effective fraction from Ampelopsis Radix with anti-dengue virus activities in vitro and in vivo

Liang-Ge-San inhibits dengue virus serotype 2 infection by reducing caveolin1-induced cytoplasmic heat shock protein 70 translocation into the plasma membrane

Antiviral activity of silymarin and baicalein against dengue virus

Discovery of Dengue Virus Ns4b Inhibitors

Inhibition of Dengue Virus by an Ester Prodrug of an Adenosine Analog

Quassinoids from Eurycoma longifolia with antiviral activities by inhibiting dengue virus replication

Réarrangements chromosomiques dans les génomes de mammifères : caractérisation des points de cassure. (Chromosomal rearrangements in mammalian genomes : characterising the breakpoints)

The identification of active compounds in Ganoderma lucidum var. antler extract inhibiting dengue virus serine protease and its computational studies

Molecular docking and dynamics simulation reveal withanolides as potent antivirals against dengue virus

exploration of potent flavonoids for dengue therapeutics

Harnessing defective interfering particles and lipid nanoparticles for effective delivery of an anti-dengue virus RNA therapy

Inhibition of dengue viruses by N-methylcytisine thio derivatives through targeting viral envelope protein and NS2B-NS3 protease

An Adenosine Nucleoside Inhibitor of Dengue Virus.

[Cancer--an environmental product?].

Design, synthesis, discovery and SAR of the fused tricyclic derivatives of indoline and imidazolidinone against DENV replication and infection